2024
Genomic insights into the comorbidity between type 2 diabetes and schizophrenia
Arruda A, Khandaker G, Morris A, Smith G, Huckins L, Zeggini E. Genomic insights into the comorbidity between type 2 diabetes and schizophrenia. Schizophrenia 2024, 10: 22. PMID: 38383672, PMCID: PMC10881980, DOI: 10.1038/s41537-024-00445-5.Peer-Reviewed Original ResearchBody mass indexType 2 diabetesType 2 diabetes riskEffect of body mass indexPutative effector genesN-methyl-D-aspartatePublic health challengeIncreased body mass indexLipid-related pathwaysRisk-increasing effectMulti-omics dataMendelian randomizationPotential causal relationshipGene expression studiesDirection of effectMental healthDrug repurposing opportunitiesAssociation signalsGenomic lociGenomic insightsHealth challengesEffector genesGenetic liabilityMass indexExpression studies
2023
W22. DISENTANGLING THE ROLES OF GENETICS AND BODY MASS INDEX ACROSS PSYCHIATRIC DISORDERS
Signer R, Seah C, Young H, de Pins A, Johnson J, Cote A, Huckins L. W22. DISENTANGLING THE ROLES OF GENETICS AND BODY MASS INDEX ACROSS PSYCHIATRIC DISORDERS. European Neuropsychopharmacology 2023, 75: s116. DOI: 10.1016/j.euroneuro.2023.08.213.Peer-Reviewed Original ResearchExpression quantitative trait lociBody mass indexGenome-wide association studiesEffect of body mass indexAssociation studiesAvailability of genome-wide association studyGenetic riskPhenome-wide association studyIndirect effect of body mass indexPsychiatric disordersBody mass index spectrumStatistical fine-mappingQuantitative trait lociGenetic risk modelsCell-type specific mannerTissue enrichmentImpact of body mass indexGWAS lociTranscriptome imputationGenomic lociWhole genomeFine-mappingTrait lociGenomic underpinningsPhenotypic consequences